Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + pemetrexed + platinum vs placebo + pemetrexed + platinum in first-line non-squamous NSCLC
CTR20180975Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in Non-small cell lung cancer (NS-NSCLC), sponsored by Innovent Biologics. Started Jul 2018; status: completed.
02
Drugs
sintilimab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20180975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180975.